Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Bladder Cancer: Page 2
AnchorDx bladder cancer test gets FDA 'breakthrough' designation
The test, UriFind, received the first breakthrough designation granted to a company in China for a liquid biopsy test for bladder cancer detection. The test is as accurate as a cystoscopy and significantly better than exfoliative cytology and fluorescence in situ hybridization (FISH) in detecting early and nonmuscle-invasive bladder cancer, according to the company.
July 20, 2021
Natera and BGI launch new assay in China
The Signatera assay was tested in studies in nonsmall cell lung, bladder, breast, and colorectal cancers and identifies MRD up to two years earlier than standard imaging, the companies said in a release.
June 23, 2021
Nucleix showcases Bladder EpiCheck at EAU 2020
The first presentation, titled "Feasibility of the EpiCheck test in upper tract tumor: Interim analysis of a prospective trial," described the evaluation of 47 patients who had undergone ureteroscopy for primary or recurrent upper tract urothelial cancer (UTUC) since June 1, 2018. Each patient had cytology and Bladder EpiCheck tests performed on voided urine and selective urine samples. Researchers found that 46% of patients were positive for UTUC as confirmed by endoscopic biopsy, half of which were high-grade. The interim analysis reported a significantly higher overall sensitivity of Bladder EpiCheck compared with cytology in voided urine (75% versus 39%). Bladder EpiCheck also displayed a higher sensitivity than cytology in high-grade UTUC (89% versus 64%) and a negative predictive value (NPV) of 95% versus 88% in voided urine.
July 19, 2020
Nucleix highlights data for urine test in detecting bladder cancer
In a study of 374 patients at Agostino Gemelli University Hospital in Rome, Italy, the firm's methylation-based assay outperformed cytology alone and yielded high sensitivity, specificity, and negative predictive value, Nucleix said. The findings support the use of Bladder EpiCheck to detect recurrence of NMIBC in patients who have undergone instillations, according to the vendor.
June 29, 2020
Google reports pathology AI helps predict survival in cancer patients
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
KDx bladder cancer urine test gets breakthrough designation
The test screens for keratin 17, a protein biomarker for urothelial cancer. It was invented by KDx co-founder Nam Kim, PhD, with research groundwork contributed by Dr. Kenneth Shroyer, PhD, chair of pathology at Stony Brook Medicine. KDx is positioning it as a noninvasive alternative to cystoscopy, which involves the insertion of a hollow tube with a lens through the urethra into the bladder.
January 9, 2020
LabCorp launches Qiagen's FGFR test for bladder cancer
The FGFR Rotor-Gene Q (RGQ) reverse transcription polymerase chain reaction (RT-PCR) kit is the first product introduced through LabCorp's participation with Qiagen in a lab readiness program aimed at making new companion diagnostics available for drugs soon after approval by the U.S. Food and Drug Administration (FDA).
May 9, 2019
Natera touts liquid biopsy in bladder cancer
Researchers evaluated use of the test in 68 patients with muscle invasive bladder cancer who received neoadjuvant chemotherapy before cystectomy at Aarhus University in Denmark. They examined a total of 656 blood samples taken at the time of diagnosis, during chemotherapy treatment, before cystectomy, and in post-treatment monitoring.
May 8, 2019
Previous Page
Page 2 of 2
